However, at the first panel meeting (December 19, 2021), this draft was considered to be inappropriate based on the limited information from a single sub-analysis study, considering that CKD patients with a history of cancer could benefit from ESA treatment (such as improvement of levels of Hb and QOLs). Here, GSTM1 is linked to cancer.